Second-line treatment in advanced pancreatic cancer: A comprehensive analysis of published clinical trials

Annals of Oncology

Volumn 24, Issue 8, 2013, Pages 1972-1979

  Rahma, O E ^a   Duffy, A ^a   Liewehr, D J ^a   Steinberg, S M ^a   Greten, T F ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Analysis; Cancer; Pancreatic; Review; Second line; Treatment

Indexed keywords

CAPECITABINE; CISPLATIN; EPIRUBICIN; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; IRINOTECAN; OXALIPLATIN; PACLITAXEL; PLATINUM COMPLEX; RALTITREXED; RUBITECAN; TAXANE DERIVATIVE;

ADVANCED CANCER; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER LOCALIZATION; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; HUMAN; MAJOR CLINICAL STUDY; METASTASIS; OVERALL SURVIVAL; PANCREAS CANCER; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SECONDARY HEALTH CARE; SURVIVAL TIME; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT PLANNING;

ANALYSIS; CANCER; PANCREATIC; REVIEW; SECOND-LINE; TREATMENT;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRIDGED COMPOUNDS; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; FLUOROURACIL; HUMANS; PANCREATIC NEOPLASMS; PLATINUM COMPOUNDS; PROTEIN KINASE INHIBITORS; QUINAZOLINES; SURVIVAL; TAXOIDS;

EID: 84881239893     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt166     Document Type: Article

References (65)

1. Jemal A, Siegel R, Xu J et al. Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277-300.
2. Sener SF, Fremgen A, Menck HR et al. Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985-1995, using the National Cancer Database. J Am Coll Surg 1999; 189: 1-7.
3. Burris H, Storniolo AM. Assessing clinical benefit in the treatment of pancreas cancer: gemcitabine compared to 5-fluorouracil. Eur J Cancer 1997; 33(Suppl 1): S18-S22.
4. Louvet C, Labianca R, Hammel P et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol 2005; 23: 3509-3516.
5. Heinemann V, Labianca R, Hinke A et al. Increased survival using platinum analog combined with gemcitabine as compared to single-agent gemcitabine in advanced pancreatic cancer: pooled analysis of two randomized trials, the GERCOR/GISCAD intergroup study and a German multicenter study. Ann Oncol 2007; 18: 1652-1659.
6. Sultana A, Tudur Smith C, Cunningham D et al. Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer: results of secondary end points analyses. Br J Cancer 2008; 99: 6-13.
7. Conroy T, Desseigne F, Ychou M et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011; 364: 1817-1825.
8. Heinemann V, Haas M, Boeck S. Systemic treatment of advanced pancreatic cancer. Cancer Treat Rev 2012; 38: 843-853.
9. Jacobs AD, Burris HA, Rivkin S et al. A randomized phase III study of rubitecan (ORA) vs. best choice (BC) in 409 patients with refractory pancreatic cancer report from a North-American multi-center study. J Clin Oncol 2004; 22(Suppl); Abstr 4013.
10. Pelzer U, Schwaner I, Stieler J et al. Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for secondline advanced pancreatic cancer: a phase III-study from the German CONKOstudy group. Eur J Cancer 2011; 47: 1676-1681.
11. Moore MJ, Goldstein D, Hamm J et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007; 25: 1960-1966.
12. Milella M, Gelibter A, Di Cosimo S et al. Pilot study of celecoxib and infusional 5- fluorouracil as second-line treatment for advanced pancreatic carcinoma. Cancer 2004; 101: 133-138.
13. Pino MS, Milella M, Gelibter A et al. Capecitabine and celecoxib as second-line treatment of advanced pancreatic and biliary tract cancers. Oncology 2009; 76: 254-261.
14. Brell JM, Matin K, Evans T et al. Phase II study of docetaxel and gefitinib as second-line therapy in gemcitabine pretreated patients with advanced pancreatic cancer. Oncology 2009; 76: 270-274.
15. Wolpin BM, Hezel AF, Abrams T et al. Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer. J Clin Oncol 2009; 27: 193-198.
16. Astsaturov IA, Meropol NJ, Alpaugh RK et al. Phase II and coagulation cascade biomarker study of bevacizumab with or without docetaxel in patients with previously treated metastatic pancreatic adenocarcinoma. Am J Clin Oncol 2011; 34: 70-75.
17. Ignatiadis M, Polyzos A, Stathopoulos GP et al. A multicenter phase II study of docetaxel in combination with gefitinib in gemcitabine-pretreated patients with advanced/metastatic pancreatic cancer. Oncology 2006; 71: 159-163.
18. O'Reilly EM. A phase II trial of sunitinib (S) in previously-treated pancreas adenocarcinoma (PAC), CALGB 80603. J Clin Oncol 2008; 26(Suppl); Abstr 4515.
19. Burris HA, III, Rivkin S, Reynolds R et al. Phase II trial of oral rubitecan in previously treated pancreatic cancer patients. Oncologist 2005; 10: 183-190.
20. Cereda S, Reni M, Rognone A et al. Salvage therapy with mitomycin and ifosfamide in patients with gemcitabine-resistant metastatic pancreatic cancer: a phase II trial. Chemotherapy 2011; 57: 156-161.
21. Pelzer U, Stieler J, Roll L et al. Second-line therapy in refractory pancreatic cancer. results of a phase II study. Onkologie 2009; 32: 99-102.
22. Pelzer U, Kubica K, Stieler J et al. A randomized trial in patients with gemcitabine refractory pancreatic cancer. Final results of the CONKO 003 study. J Clin Oncol 2008; 26(Suppl); Abstr 4508.
23. Morizane C, Okusaka T, Furuse J et al. A phase II study of S-1 in gemcitabinerefractory metastatic pancreatic cancer. Cancer Chemother Pharmacol 2009; 63: 313-319.
24. Heinemann V, Vehling-Kaiser U, Waldschmidt D et al. Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer: final results of a randomised phase 3 trial of the 'Arbeitsgemeinschaft Internistische Onkologie' (AIO-PK0104). Gut 2012; 62: 751-759.
25. Androulakis N, Syrigos K, Polyzos A et al. Oxaliplatin for pretreated patients with advanced or metastatic pancreatic cancer: a multicenter phase II study. Cancer Invest 2005; 23: 9-12.
26. Tsavaris N, Kosmas C, Skopelitis H et al. Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: a phase II study. Invest New Drugs 2005; 23: 369-375.
27. Novarino A, Satolli MA, Chiappino I et al. Oxaliplatin, 5-fluorouracil, and leucovorin as second-line treatment for advanced pancreatic cancer. Am J Clin Oncol 2009; 32: 44-48.
28. Gebbia V, Maiello E, Giuliani F et al. Second-line chemotherapy in advanced pancreatic carcinoma: a multicenter survey of the Gruppo Oncologico Italia Meridionale on the activity and safety of the FOLFOX4 regimen in clinical practice. Ann Oncol 2007; 18(Suppl 6): vi124-vi127.
29. Xiong HQ, Varadhachary GR, Blais JC et al. Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second-line therapy for patients with advanced pancreatic cancer. Cancer 2008; 113: 2046-2052.
30. Togawa A, Yoshitomi H, Ito H et al. Treatment with an oral fluoropyrimidine, S-1, plus cisplatin in patients who failed postoperative gemcitabine treatment for pancreatic cancer: a pilot study. Int J Clin Oncol 2007; 12: 268-273.
31. Yoo C, Hwang JY, Kim JE et al. A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer. Br J Cancer 2009; 101: 1658-1663.
32. Dahan L, Bonnetain F, Ychou M et al. Combination 5-fluorouracil, folinic acid and cisplatin (LV5FU2-CDDP) followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: final results of a randomised strategic phase III trial (FFCD 0301). Gut 2010; 59: 1527-1534.
33. Mitry E, Ducreux M, Ould-Kaci M et al. Oxaliplatin combined with 5-FU in second line treatment of advanced pancreatic adenocarcinoma. Results of a phase II trial. Gastroenterol Clin Biol 2006; 30: 357-363.
34. Gasent Blesa J, Alberola-Candel V, Giner Marco V et al. Phase II trial of secondline chemotherapy in metastatic pancreas cancer with the combination of oxaliplatin (Ox) and capecitabine (Cp). J Clin Oncol 2009; 27(Suppl); Abstr 15561.
35. Yi SY, Park YS, Kim HS et al. Irinotecan monotherapy as second-line treatment in advanced pancreatic cancer. Cancer Chemother Pharmacol 2009; 63: 1141-1145.
36. Cantore M, Rabbi C, Fiorentini G et al. Combined irinotecan and oxaliplatin in patients with advanced pre-treated pancreatic cancer. Oncology 2004; 67: 93-97.
37. Ko AH, Tempero MA, Shan Y et al. A multinational phase II study of liposome irinotecan (PEP02) for patients with gemcitabine-refractory metastatic pancreatic cancer. J Clin Oncol 2011; 29(Suppl 4); Abst 237.
38. Ulrich-Pur H, Raderer M, Verena Kornek G et al. Irinotecan plus raltitrexed vs raltitrexed alone in patients with gemcitabine-pretreated advanced pancreatic adenocarcinoma. Br J Cancer 2003; 88: 1180-1184.
39. Boeck S, Weigang-Kohler K, Fuchs M et al. Second-line chemotherapy with pemetrexed after gemcitabine failure in patients with advanced pancreatic cancer: a multicenter phase II trial. Ann Oncol 2007; 18: 745-751.
40. Oettle H, Arnold D, Esser M et al. Paclitaxel as weekly second-line therapy in patients with advanced pancreatic carcinoma. Anticancer Drugs 2000; 11: 635-638.
41. Katopodis O, Polyzos A, Kentepozidis N et al. Second-line chemotherapy with capecitabine (Xeloda) and docetaxel (Taxotere) in previously treated, unresectable adenocarcinoma of pancreas: the final results of a phase II trial. Cancer Chemother Pharmacol 2011; 67: 361-368.
42. Reni M, Pasetto L, Aprile G et al. Raltitrexed-eloxatin salvage chemotherapy in gemcitabine-resistant metastatic pancreatic cancer. Br J Cancer 2006; 94: 785-791.
43. Blaya M, Lopes GL, Roman Jr E et al. Phase II trial of capecitabine and docetaxel as second line therapy for locally advanced and metastatic pancreatic cancer. J Clin Oncol 2007; 25(Suppl); Abstr 15029.
44. Hosein PJ, Pastorini VH, Gomez CM et al. A phase II trial of nab-paclitaxel (NP) in patients with advanced pancreatic cancer (PC) who have progressed on gemcitabine-based therapy. In Gastrointestinal Cancers Symposium 2010; Abstr 214.
45. Demols A, Peeters M, Polus M et al. Gemcitabine and oxaliplatin (GEMOX) in gemcitabine refractory advanced pancreatic adenocarcinoma: a phase II study. Br J Cancer 2006; 94: 481-485.
46. Stathopoulos GP, Boulikas T, Vougiouka M et al. Liposomal cisplatin combined with gemcitabine in pretreated advanced pancreatic cancer patients: a phase I-II study. Oncol Rep 2006; 15: 1201-1204.
47. Reni M, Cereda S, Mazza E et al. PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) regimen as second-line therapy in patients with progressive or recurrent pancreatic cancer after gemcitabine-containing chemotherapy. Am J Clin Oncol 2008; 31: 145-150.
48. Kozuch P, Grossbard ML, Barzdins A et al. Irinotecan combined with gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (G-FLIP) is an effective and noncrossresistant treatment for chemotherapy refractory metastatic pancreatic cancer. Oncologist 2001; 6: 488-495.
49. Fortune BE, Li X, Kosuri KV et al. Fixed-dose-rate gemcitabine in combination with oxaliplatin in patients with metastatic pancreatic cancer refractory to standarddose- rate gemcitabine: a single-institute study. Oncology 2009; 76: 333-337.
50. Kulke MH, Blaszkowsky LS, Ryan DP et al. Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer. J Clin Oncol 2007; 25: 4787-4792.
51. Tang P, Gill S, Au HJ et al. Phase II trial of erlotinib in advanced pancreatic cancer (PC). J Clin Oncol 2009; 27(Suppl); Abstr 4609.
52. Ko AH, Dito E, Schillinger B et al. A phase II study of bevacizumab (BEV) plus erlotinib (ERL) in patients with gemcitabine (GEM)-refractory metastatic pancreatic cancer (MPC). J Clin Oncol 2008; 26(Suppl); Abstr 4516.
53. Group MRCOCW. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet 2002; 359: 1727-1733.
54. Goldberg RM. N9741: a phase III study comparing irinotecan to oxaliplatincontaining regimens in advanced colorectal cancer. Clin Colorectal Cancer 2002; 2: 81.
55. Hanna N, Shepherd FA, Fossella FV et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004; 22: 1589-1597.
56. Citron ML, Berry DA, Cirrincione C et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003; 21: 1431-1439.
57. Thuss-Patience PC, Kretzschmar A, Bichev D et al. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer-a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Eur J Cancer 2011; 47: 2306-2314.
58. Cunningham D, Pyrhonen S, James RD et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998; 352: 1413-1418.
59. Kim MP, Gallick GE. Gemcitabine resistance in pancreatic cancer: picking the key players. Clin Cancer Res 2008; 14: 1284-1285.
60. Andersson R, Aho U, Nilsson BI et al. Gemcitabine chemoresistance in pancreatic cancer: molecular mechanisms and potential solutions. Scand J Gastroenterol 2009; 44: 782-786.
61. Eisenhauer EA, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-247.
62. Tas F, Sen F, Odabas H et al. Performance status of patients is the major prognostic factor at all stages of pancreatic cancer. Int J Clin Oncol 2012 September 21 [epub ahead of print], doi: 10.1007/s10147-012-0474-9.
63. Feig C, Gopinathan A, Neesse A et al. The pancreas cancer microenvironment. Clin Cancer Res 2012; 18: 4266-4276.
64. Iacobuzio-Donahue CA, Velculescu VE, Wolfgang CL et al. Genetic basis of pancreas cancer development and progression: insights from whole-exome and whole-genome sequencing. Clin Cancer Res 2012; 18: 4257-4265.
65. Li C, Heidt DG, Dalerba P et al. Identification of pancreatic cancer stem cells. Cancer Res 2007; 67: 1030-1037.